» Articles » PMID: 22929025

A Rare Variant in the Osteoarthritis-associated Locus GDF5 is Functional and Reveals a Site That Can Be Manipulated to Modulate GDF5 Expression

Overview
Journal Eur J Hum Genet
Specialty Genetics
Date 2012 Aug 30
PMID 22929025
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoarthritis (OA) is a polygenic disease characterized by cartilage loss, with the single-nucleotide polymorphism (SNP) rs143383 (C/T) influencing OA susceptibility across a range of ethnic groups. The SNP resides within the 5'-UTR of the growth and differentiation factor 5 gene (GDF5), with the OA-associated T-allele mediating reduced GDF5 expression. As GDF5 codes for a cartilage anabolic protein, this reduced expression may explain why the T-allele of rs143383 is an OA risk factor. Our deep sequencing of GDF5 identified a C/A transversion located -41 bp relative to the gene's transcription start site. This promoter variant is predicted to affect transcription factor binding and it may therefore highlight a regulatory site that could be exploited to manipulate GDF5 expression and alleviate the detrimental effect mediated by the T-allele of rs143383. Here, we describe our functional assessment of the -41 bp variant. Using reporter constructs we demonstrated that the transversion leads to increased gene expression to such a degree that the A-allele is able to compensate for the reduced expression mediated by the T-allele of rs143383. Using electrophoretic mobility shift assays we identified YY1 as a trans-acting factor that differentially binds to the alleles of the -41 bp variant, with more avid binding to allele A. Knockdown of YY1 led to a significant reduction in GDF5 expression, supporting YY1 as a GDF5 activator. In conclusion, we demonstrated that the -41 bp variant is functional and we have identified a regulatory region of GDF5 that can be exploited to overcome the OA genetic deficit mediated by the T-allele of rs143383.

Citing Articles

Transforming growth factor beta signaling and craniofacial development: modeling human diseases in zebrafish.

Fox S, Waskiewicz A Front Cell Dev Biol. 2024; 12:1338070.

PMID: 38385025 PMC: 10879340. DOI: 10.3389/fcell.2024.1338070.


Joint disease-specificity at the regulatory base-pair level.

Muthuirulan P, Zhao D, Young M, Richard D, Liu Z, Emami A Nat Commun. 2021; 12(1):4161.

PMID: 34230488 PMC: 8260791. DOI: 10.1038/s41467-021-24345-9.


Growth differentiation factor 5 in cartilage and osteoarthritis: A possible therapeutic candidate.

Sun K, Guo J, Yao X, Guo Z, Guo F Cell Prolif. 2021; 54(3):e12998.

PMID: 33522652 PMC: 7941218. DOI: 10.1111/cpr.12998.


The GDF-5 mutant M1673 exerts robust anabolic and anti-catabolic effects in chondrocytes.

Mang T, Kleinschmidt-Dorr K, Ploeger F, Lindemann S, Gigout A J Cell Mol Med. 2020; 24(13):7141-7150.

PMID: 32497388 PMC: 7339174. DOI: 10.1111/jcmm.15149.


Genetic Association Between Growth Differentiation Factor 5 Single Nucleotide Polymorphism and Primary Knee Osteoarthritis in a Group of Egyptian Patients: A Pilot Study.

Mohasseb D, Saba E, Saad N, Sarofeem A Mediterr J Rheumatol. 2020; 30(2):114-122.

PMID: 32185351 PMC: 7045969. DOI: 10.31138/mjr.30.2.114.


References
1.
Southam L, Rodriguez-Lopez J, Wilkins J, Pombo-Suarez M, Snelling S, Gomez-Reino J . An SNP in the 5'-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. Hum Mol Genet. 2007; 16(18):2226-32. DOI: 10.1093/hmg/ddm174. View

2.
Chapman K, Takahashi A, Meulenbelt I, Watson C, Rodriguez-Lopez J, Egli R . A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5' UTR of GDF5 with osteoarthritis susceptibility. Hum Mol Genet. 2008; 17(10):1497-504. DOI: 10.1093/hmg/ddn038. View

3.
He Y, Casaccia-Bonnefil P . The Yin and Yang of YY1 in the nervous system. J Neurochem. 2008; 106(4):1493-502. PMC: 2642738. DOI: 10.1111/j.1471-4159.2008.05486.x. View

4.
Ratnayake M, Reynard L, Raine E, Santibanez-Koref M, Loughlin J . Allelic expression analysis of the osteoarthritis susceptibility locus that maps to MICAL3. BMC Med Genet. 2012; 13:12. PMC: 3366887. DOI: 10.1186/1471-2350-13-12. View

5.
Roy A, McDonald P, Sittampalam S, Chaguturu R . Open access high throughput drug discovery in the public domain: a Mount Everest in the making. Curr Pharm Biotechnol. 2010; 11(7):764-78. PMC: 3716285. DOI: 10.2174/138920110792927757. View